Related Experiment Video
Updated: Jun 22, 2026
11:01
Ferromagnetic Bare Metal Stent for Endothelial Cell Capture and Retention
Published on: September 18, 2015
Experimental evaluation of a new antithrombogenic stent using ion beam surface modification
Yoichi Sugita1, Yoshiaki Suzuki, Kenji Someya
1Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. sugita@bcm.edu
Artificial Organs
|May 29, 2009
Summary
A novel ion beam surface modification technique significantly improved stent performance. This antithrombogenic stent shows promise for preventing blood clots in coronary and cerebral applications.
Area of Science:
- Biomaterials Engineering
- Nanotechnology
- Medical Device Development
Background:
- Stent-related thrombosis remains a significant clinical challenge, necessitating improved antithrombogenic strategies.
- Current treatments often require long-term anticoagulant or antiplatelet therapy, increasing bleeding risks.
- Surface modification of metallic stents offers a potential solution to enhance biocompatibility and reduce thrombogenicity.
Purpose of the Study:
- To evaluate the antithrombogenic properties of a novel stent modified using ion beam surface nanotechnology.
- To assess the efficacy of helium ion (He+) beam irradiation on collagen-coated titanium-nickel (Ti-Ni) stents in preventing thrombosis.
- To determine the long-term patency and biocompatibility of the modified stents in a preclinical model.
Main Methods:
- Thirty Ti-Ni self-expanding mesh stents were fabricated.
- Twenty stents were coated with type I collagen and irradiated with a He+ ion beam (150 keV, 1 x 10(14) ions/cm(2)).
- Ten control stents received no treatment. Stents were implanted in beagle dog femoral arteries, and patency was assessed over 2 years without post-implantation antithrombotic drugs.
Main Results:
- The ion-modified stent group demonstrated a significantly higher 1-month patency rate (80%) compared to the non-modified group (10%) (P = 0.0004).
- Ten ion-modified stents remained patent for up to 2 years post-implantation.
- No anticoagulant or antiplatelet drugs were administered post-implantation, highlighting the inherent antithrombogenicity of the modified stent.
Conclusions:
- Helium ion-implanted, collagen-coated Ti-Ni self-expanding stents exhibit excellent antithrombogenicity and biocompatibility.
- This nanotechnology-based surface modification effectively inhibits stent-related thrombosis.
- The developed ion stent shows significant potential for applications in coronary and cerebral arteries, potentially reducing the need for post-procedural medication.
